logo
products

Entrectinib 100mg*60 Capsules for NTRK Fusion Solid Tumors

Basic Information
Place of Origin: Laos
Brand Name: PHOENTRE
Model Number: RXDX-101
Minimum Order Quantity: 1 PCS
Price: Please contact a specialist WhatsApp:55342706
Packaging Details: Negotiable
Delivery Time: Negotiable
Payment Terms: Western Union,MoneyGram,T/T
Supply Ability: Negotiable
Detail Information
Specifications:: 100mg*60 Capsules/bottle (box) Indications: Kidney Cancer, Thyroid Cancer, Liver Cancer, Soft Tissue Sarcoma, Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Ovarian Cancer, Bowel Cancer
Target: NRTK1/2/3、ALK、ROS1 Product Name: Entrectinib
Recommended Dose: Please Follow Doctor's Advice Storage: Sealed And Stored No More Than 30℃.
Highlight:

phoentre treatment drugs Entrectinib 100mg

,

PHOENTRE 100mg Chemotherapy Pills

,

Chemotherapy Pills PHOENTRE 100mg


Product Description

Entrectinib (Rozlytrek®) 200mg*90 tablets
Pan-tumor targeting immune drug for stage 1, 2, 3 cancer treatment. Targets NRTK1/2/3, ALK, ROS1.
Product Specifications
Attribute Value
Specifications 100mg*60 capsules/bottle (box)
Indications Kidney cancer, thyroid cancer, liver cancer, soft tissue sarcoma, non-small cell lung cancer, prostate cancer, breast cancer, ovarian cancer, bowel cancer
Target NRTK1/2/3, ALK, ROS1
Product name Entrectinib
Recommended dose Please follow doctor's advice
Storage Sealed and stored no more than 30℃
Drug Information
Generic name: Entrectinib capsules
Product name: Rozlytrek®
Chinese Pinyin: Enqutini Jiaonan
Indications
Solid tumors: Suitable for adults and children aged 12+ with solid tumors who have NTRK fusion gene confirmed by validated test, with locally advanced/metastatic disease or where surgery may cause serious complications, and no satisfactory alternative treatments.
Non-small cell lung cancer (NSCLC): For adult patients with ROS1-positive locally advanced or metastatic NSCLC.
This indication has been conditionally approved based on surrogate endpoints. Clinical endpoint data not yet available.
Dosage Information
Treatment should be initiated by physician experienced in anti-cancer treatment. Must confirm NTRK fusion gene (for solid tumors) or ROS1-positive status (for NSCLC) before treatment.
Recommended Dosage
Oral administration. Swallow capsules whole (do not open/dissolve). May take with/without food, but avoid grapefruit/grapefruit juice.
  • Adults: 600 mg once daily
  • Pediatric (12+ years): 300 mg/m² once daily (see dosage tables)
Treatment Duration
Continue until disease progression or intolerable toxicity occurs.
Dosage Adjustments
Detailed dosage adjustment tables available for:
  • Adult dose reduction plan
  • Pediatric dose reduction scheme
  • Adjustments for specific adverse reactions
  • Special populations (elderly, renal/hepatic impairment)
For complete dosage information, see Entrectinib dose guidelines.
Side Effects
Most common adverse reactions (≥20%): fatigue, constipation, dysgeusia, edema, dizziness, diarrhea, nausea, hypoesthesia, dyspnea, anemia, weight gain, increased serum creatinine, pain, cognitive impairment, vomiting, cough, fever.
Serious adverse reactions (≥2%): pulmonary infection (5.2%), dyspnea (4.6%), cognitive impairment (3.8%), pleural effusion (3.0%), fracture (2.4%).
4.6% of patients permanently discontinued treatment due to adverse reactions.
For complete safety information, see Entrectinib side effects.
Storage
Sealed and stored no more than 30℃.
For complete storage information, see Entrectinib package insert.
Entrectinib 100mg*60 Capsules for NTRK Fusion Solid Tumors 0

Contact Details
Roy

Phone Number : 13313517590

WhatsApp : +8613313517590